Clinical Trials
51 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
ANTARES
Instituto do Cancer do Estado de São Paulo
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Kaiser Permanente
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
AYAConnect
UNC Lineberger Comprehensive Cancer Center
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
KEYNOTE 158
Merck Sharp & Dohme LLC
EARN
Washington University School of Medicine
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
AMPLIFY
University of Alabama at Birmingham
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
ACROPOLI
SOLTI Breast Cancer Research Group
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Universidade Federal de Pernambuco
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
CAPABLE-IT
Istituti Clinici Scientifici Maugeri SpA
AcSé
UNICANCER
OPTI-DOSE
University Medical Center Groningen
ALpha-T
Hoffmann-La Roche
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
RESTORE
Blue Note Therapeutics
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Zhujiang Hospital
SIGNATURE
Novartis
Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors
University of Alabama at Birmingham
Spectroscopy With Surface Coils and Decoupling
Memorial Sloan Kettering Cancer Center
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey